1
|
Zhalsanova IZ, Ravzhaeva EG, Postrigan AE, Seitova GN, Zhigalina DI, Udalova VY, Danina MM, Kanivets IV, Skryabin NA. Case Report: Compound Heterozygous Variants of the MAN1B1 Gene in a Russian Patient with Rafiq Syndrome. Int J Mol Sci 2022; 23:ijms231810606. [PMID: 36142510 PMCID: PMC9502887 DOI: 10.3390/ijms231810606] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2022] [Revised: 09/07/2022] [Accepted: 09/08/2022] [Indexed: 12/02/2022] Open
Abstract
Rafiq syndrome (RAFQS) is a congenital disorder of glycosylation (CDG) that is caused by mutations in the MAN1B1 gene and characterized by impaired protein and lipid glycosylation. RAFQS is characterized by a delay in intellectual and motor development, facial and other dysmorphism, truncal obesity, behavior problems, and hypotonia. We describe a Russian patient with delayed intellectual and motor development, a lack of speech, disorientation in space and time, impaired attention and memory, and episodes of aggression. Screening for lysosomal, amino acid, organic acid, and mitochondrial disorders was normal. The patient was referred for the targeted sequencing of the “Hereditary Metabolic Disorders” panel. The genetic testing revealed two heterozygous pathogenic variants in the MAN1B1 gene: the previously reported c.1000C > T (p.Arg334Cys) and the novel c.1065 + 1 G > C. Thus, the patient’s clinical picture and genetic analysis confirmed RAFQS in the patient.
Collapse
Affiliation(s)
- Irina Zh. Zhalsanova
- Tomsk National Research Medical Center, Research Institute of Medical Genetics, 634050 Tomsk, Russia
- Correspondence: (I.Z.Z.); (N.A.S.); Tel.: +7-(923)-419-94-94 (I.Z.Z.)
| | - Ekatherina G. Ravzhaeva
- Tomsk National Research Medical Center, Research Institute of Medical Genetics, 634050 Tomsk, Russia
| | - Anna E. Postrigan
- Tomsk National Research Medical Center, Research Institute of Medical Genetics, 634050 Tomsk, Russia
| | - Gulnara N. Seitova
- Tomsk National Research Medical Center, Research Institute of Medical Genetics, 634050 Tomsk, Russia
| | - Daria I. Zhigalina
- Tomsk National Research Medical Center, Research Institute of Medical Genetics, 634050 Tomsk, Russia
| | | | | | | | - Nikolay A. Skryabin
- Tomsk National Research Medical Center, Research Institute of Medical Genetics, 634050 Tomsk, Russia
- Correspondence: (I.Z.Z.); (N.A.S.); Tel.: +7-(923)-419-94-94 (I.Z.Z.)
| |
Collapse
|
2
|
Identification of MAN1B1 as a Novel Marker for Bladder Cancer and Its Relationship with Immune Cell Infiltration. JOURNAL OF ONCOLOGY 2022; 2022:3387671. [PMID: 36016584 PMCID: PMC9398811 DOI: 10.1155/2022/3387671] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/13/2022] [Revised: 07/10/2022] [Accepted: 07/12/2022] [Indexed: 11/25/2022]
Abstract
Bladder cancer (BC) is a common malignant tumor of the genitourinary system, and there are not enough tumor biomarker tests that are specific, trustworthy, and noninvasive for the diagnosis and prognosis. The purpose of this study is to investigate the clinical relevance, prognostic value, and immunological signature of Mannosidase alpha class 1B member 1(MAN1B1) expressions in BC. The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases provided the raw information that was used to analyze the expression of MAN1B1 in tumor patients. Then, a statistical study was carried out to assess the correlations of MAN1B1 expression with the clinical characteristics and the prognosis of BC. The correlation between MAN1B1 expression and tumor immune infiltration was explored via single-sample gene set enrichment analysis (ssGSEA). In human cancers, MAN1B1 expressions were shown to be generally higher in tumors than in normal specimens. We confirmed that MAN1B1 expression was distinctly increased in BC specimens compared with nontumor specimens. BC specimens with advanced T stage and M stage showed a higher level of MAN1B1. Survival analysis revealed that the overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI) of patients with high MAN1B1 expressions were distinctly worse than those with low MAN1B1 expressions. Importantly, multivariate analyses only confirmed that MAN1B1 expression was an independent prognostic factor for OS of the patients with BC. Furthermore, we observed that MAN1B1 expression level was significantly correlated with abundance of multiple immune infiltrates including Th2 cells, macrophages, Th1 cells, neutrophils, T helper cells, and NK CD56 bright cells. In conjunction with all of these findings, elevated MAN1B1 expression is associated with a poor prognosis and a higher number of immune cells in BC. MAN1B1 has the potential to act as a biomarker that can evaluate both the patient's prognosis and the degree of immune infiltration in BC.
Collapse
|
3
|
Okamoto N, Ohto T, Enokizono T, Wada Y, Kohmoto T, Imoto I, Haga Y, Seino J, Suzuki T. Siblings with MAN1B1-CDG Showing Novel Biochemical Profiles. Cells 2021; 10:cells10113117. [PMID: 34831340 PMCID: PMC8618856 DOI: 10.3390/cells10113117] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2021] [Revised: 11/02/2021] [Accepted: 11/05/2021] [Indexed: 11/16/2022] Open
Abstract
Congenital disorders of glycosylation (CDG), inherited metabolic diseases caused by defects in glycosylation, are characterized by a high frequency of intellectual disability (ID) and various clinical manifestations. Two siblings with ID, dysmorphic features, and epilepsy were examined using mass spectrometry of serum transferrin, which revealed a CDG type 2 pattern. Whole-exome sequencing showed that both patients were homozygous for a novel pathogenic variant of MAN1B1 (NM_016219.4:c.1837del) inherited from their healthy parents. We conducted a HPLC analysis of sialylated N-linked glycans released from total plasma proteins and characterized the α1,2-mannosidase I activity of the lymphocyte microsome fraction. The accumulation of monosialoglycans was observed in MAN1B1-deficient patients, indicating N-glycan-processing defects. The enzymatic activity of MAN1B1 was compromised in patient-derived lymphocytes. The present patients exhibited unique manifestations including early-onset epileptic encephalopathy and cerebral infarction. They also showed coagulation abnormalities and hypertransaminasemia. Neither sibling had truncal obesity, which is one of the characteristic features of MAN1B1-CDG.
Collapse
Affiliation(s)
- Nobuhiko Okamoto
- Department of Medical Genetics, Osaka Women’s and Children’s Hospital, Izumi 594-1101, Japan
- Department of Molecular Medicine, Research Institute, Osaka Women’s and Children’s Hospital, Izumi 594-1101, Japan;
- Correspondence:
| | - Tatsuyuki Ohto
- Department of Pediatrics, Tsukuba University Faculty of Medicine, Tsukuba 305-8576, Japan; (T.O.); (T.E.)
| | - Takashi Enokizono
- Department of Pediatrics, Tsukuba University Faculty of Medicine, Tsukuba 305-8576, Japan; (T.O.); (T.E.)
| | - Yoshinao Wada
- Department of Molecular Medicine, Research Institute, Osaka Women’s and Children’s Hospital, Izumi 594-1101, Japan;
| | - Tomohiro Kohmoto
- Division of Molecular Genetics, Aichi Cancer Center Research Institute, Nagoya 464-8681, Japan; (T.K.); (I.I.)
- Department of Human Genetics, Graduate School of Biomedical Science, Tokushima University Graduate School, Tokushima 770-8503, Japan
| | - Issei Imoto
- Division of Molecular Genetics, Aichi Cancer Center Research Institute, Nagoya 464-8681, Japan; (T.K.); (I.I.)
- Department of Human Genetics, Graduate School of Biomedical Science, Tokushima University Graduate School, Tokushima 770-8503, Japan
| | - Yoshimi Haga
- Glycometabolic Biochemistry Laboratory, RIKEN Cluster for Pioneering Research (CPR), 2-1 Hirosawa, Wako 351-0198, Japan; (Y.H.); (J.S.); (T.S.)
- Cancer Proteomics Group, Cancer Precision Medicine Center, Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo 135-8550, Japan
| | - Junichi Seino
- Glycometabolic Biochemistry Laboratory, RIKEN Cluster for Pioneering Research (CPR), 2-1 Hirosawa, Wako 351-0198, Japan; (Y.H.); (J.S.); (T.S.)
| | - Tadashi Suzuki
- Glycometabolic Biochemistry Laboratory, RIKEN Cluster for Pioneering Research (CPR), 2-1 Hirosawa, Wako 351-0198, Japan; (Y.H.); (J.S.); (T.S.)
| |
Collapse
|